| Catalog No. |
Size |
Price |
Figures |
Z00341-2 ug
| 2 ug | $ 70.00 |
References:
- Arai M, et al. Granulocyte colony-stimulating factor: a noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease. Circ. J. Sep 2006; 70(9): 1093-1098.
- Arora M, et al. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Biol. Blood Marrow Transplant. Jun 2004; 10(6): 395-404.
- Lonial S, et al. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol. Blood Marrow Transplant. Dec 2004; 10(12): 848-857.
|
|---|
| Full Name | | Granulocyte Colony Stimulating Factor (G-CSF), CHO, human |
|
| Abbreviated Name-1 | rHuG-CSF |
|---|
| Abbreviated Name-2 | Granulocyte Colony Stimulating Factor (CHO) |
| Description | Granulocyte Colony Stimulating Factor (G-CSF), CHO, human is a glycosylated, polypeptide chain containing 174 amino acids and having a molecular mass of 20,000 Da. Human G-CSF is purified by proprietary chromatographic techniques. A glycoprotein of MW 20,000 Da containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. The synthesis of G-CSF can be induced by bacterial endotoxins, TNF, Interleukin-1 and M-CSF. Prostaglandin E2 inhibits the synthesis of G-CSF. In epithelial, endothelial, and fibroblastic cells secretion of G-CSF is induced by Interleukin-17. |
| Source | Chinese Hamster Ovary Cells (CHO) |
| M.W. | 20,000 Da |
| Purity | Greater than 98.0% as determined by: (a) Analysis by RP-HPLC (b) Analysis by SDS-PAGE |
| Endotoxin Level | Less than 0.1 ng/µg (IEU/µg) of rHuG-CSF |
| Specific Activity | The ED50, calculated by the dose-dependant proliferation of murine NFS-60 indicator cells (measured by 3H-thymidine uptake) is < 0.1 ng/ml, corresponding to a Specific Activity of 1.27 x 108 IU/mg. |
| Storage | Lyophilized rHuG-CSF although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution rHuG-CSF should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles. |
| Formulation | The protein was lyophilized from a concentrated (1 mg/ml) solution containing 10 mM Hydrochloric Acid pH6.5, 0.4 mg tween 20, 100 mg mannitol, 160 mg L-arginine, 40 mg phenylalanin and 4mg methionin. |
| Reconstitution | It is recommended to reconstitute the lyophilized rHuG-CSF in sterile 18 MΩ-cm H2O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions. |
| Quantitation | Protein quantitation was carried out by two independent methods: 1. V spectroscopy at 280 nm using the absorbency value of 0.815 as the extinction coefficient for a 0.1% (1 mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a calibrated solution of G-CSF as a Reference Standard.
|
| Sequence | TPLGPASSLP QSFLLKCLEQ VRKIQGDGAA LQEKLCATYK LCHPEELVLL GHSLGIPWAP LSSCPSQALQ LAGCLSQLHS GLFLYQGLLQ ALEGISPELG PTLDTLQLDV ADFATTIWQQ MEELGMAPAL QPTQGAMPAF ASAFQRRAGG VLVASHLQSF LEVSYRVLRH LAQP |
| Sequence analysis | The sequence of the first five N-terminal amino acids was determined and was found to be Thr-Pro-Leu-Gly-Pro. |